---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-040508"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:52:31.010645+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bionano cuts workforce 45%, lowers revenue guidance to $32-36M, CFO departs

## Summary
- Reduction of ~84 employees (45% of workforce); expects $25-30M annual cost savings starting Q4 2024.
- Revenue guidance reduced to $32-36M from $36-40M due to fewer OGM instrument placements.
- CFO Gülsen Kama leaving effective Sep 18; CEO Erik Holmlin appointed principal financial officer.
- Restructuring charges estimated at $0.5-1.0M, substantially complete by Oct 1, 2024.

## SEC filing metadata
- accession: 0001140361-24-040508
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/0001140361-24-040508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/ny20035639x1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-040508
- JSON: https://secwatch.observer/filing/0001140361-24-040508.json
- Plain text: https://secwatch.observer/filing/0001140361-24-040508.txt

## Source-grounded claims
- claim_id: 7ccb6742ee
  claim: R. Erik Holmlin was appointed as Principal Financial Officer at Bionano Genomics, Inc..
  evidence_excerpt: On September 4, 2024, R. Erik Holmlin, Ph.D., President and Chief Executive Officer of the Company, was appointed by the Board of Directors (the “Board”) of the Company to serve as the principal financial officer of the Company, effective September 18, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/0001140361-24-040508-index.htm
- claim_id: 880ceba24c
  claim: Gülsen Kama departed as Chief Financial Officer at Bionano Genomics, Inc..
  evidence_excerpt: the role of our Chief Financial Officer, Gülsen Kama, was impacted and Ms. Kama will no longer be employed with the Company effective September 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/0001140361-24-040508-index.htm
- claim_id: ac0cc07b46
  claim: Mark Adamchak was appointed as Principal Accounting Officer at Bionano Genomics, Inc..
  evidence_excerpt: Mark Adamchak, Vice President of Accounting & Finance was appointed to serve as the principal accounting officer of the Company, effective September 18, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124040508/0001140361-24-040508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.